Hjazi Ahmed, Hussn Ahmed, Kareem A K, Alshahrani Mohammad Y, Malathi H, Nayak Priya Priyadarshini, Chauhan Ashish Singh, Sharma Jatin
Department of Medical Laboratory, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al-Kharj, 11942, Saudi Arabia.
Department of Medical Analysis, Medical Laboratory Technique College, The Islamic University of Al Diwaniyah, Al Diwaniyah, Iraq.
Exp Cell Res. 2025 Jul 15;450(2):114648. doi: 10.1016/j.yexcr.2025.114648. Epub 2025 Jun 10.
EZH2 (enhancer of zeste homolog 2) is an important component of the Polycomb Repressive Complex 2 (PRC2) and is essential for the epigenetic regulation of gene expression. EZH2 primarily methylates histone H3 at lysine 27 (H3K27me3) to repress target gene transcription, particularly concerning tumor suppressor genes. The silencing of these genes ultimately promotes cancer by facilitating several important processes, a notable one being epithelial-mesenchymal transition (EMT), which promotes the invasiveness and metastatic potential of cancer cells, particularly in digestive system cancers. In addition to its role in histone modification, EZH2 interacts with diverse noncoding RNA species, including long noncoding RNAs (lncRNAs) and microRNAs, which can influence expression and activity. These interactions form elaborate regulatory pathways through which EZH2 enhances its oncogenic abilities. For example, lncRNAs recruit EZH2 to specific gene promoters and promote EZH2's repressive function to repress important tumor suppressor genes seen in colon, gastric, and esophageal cancers. Also, EZH2 overexpression has been associated with poor prognosis in several cancers, including gastrointestinal cancers. EZH2 overexpression is linked with aggressive tumor behavior and contributes to therapeutic resistance as cancer cells adapt to avoid the effects of traditional cancer therapy. EZH2 allows cancer cells to persist and proliferate in response to therapy by silencing genes that control apoptosis and the cell cycle. Since EZH2 is strongly associated with poor prognosis and therapeutic resistance in digestive cancers, targeting EZH2 will be a highly effective therapeutic strategy. This in-depth review suggests that further efforts will be required to thoroughly characterize the complex molecular networks that involve EZH2, especially with the hope of generating new therapeutic pathways in malignant cancers of the digestive system.
EZH2(zeste同源物2增强子)是多梳抑制复合物2(PRC2)的重要组成部分,对基因表达的表观遗传调控至关重要。EZH2主要使组蛋白H3的赖氨酸27位点(H3K27me3)发生甲基化,以抑制靶基因转录,尤其是与肿瘤抑制基因相关的转录。这些基因的沉默最终通过促进几个重要过程来推动癌症发展,其中一个显著过程是上皮-间质转化(EMT),它促进癌细胞的侵袭性和转移潜能,尤其是在消化系统癌症中。除了在组蛋白修饰中的作用外,EZH2还与多种非编码RNA相互作用,包括长链非编码RNA(lncRNA)和微小RNA,这会影响其表达和活性。这些相互作用形成了复杂的调控途径,通过这些途径EZH2增强其致癌能力。例如,lncRNA将EZH2招募到特定基因启动子处,并促进EZH2的抑制功能,从而抑制在结肠癌、胃癌和食管癌中发现的重要肿瘤抑制基因。此外,EZH2过表达与包括胃肠道癌症在内的多种癌症的不良预后相关。EZH2过表达与侵袭性肿瘤行为相关,并导致治疗耐药,因为癌细胞会适应以避免传统癌症治疗的影响。EZH2通过沉默控制细胞凋亡和细胞周期的基因,使癌细胞在治疗后持续存在并增殖。由于EZH2与消化系统癌症的不良预后和治疗耐药密切相关,靶向EZH2将是一种高效的治疗策略。这篇深入综述表明,需要进一步努力全面表征涉及EZH2的复杂分子网络,特别是希望能在消化系统恶性肿瘤中开辟新的治疗途径。